CLINICAL_TRIALS
trial_result
· 2026-03-17
Clinical Trial Update: Cardiac Allograft Vasculopathy Inhibition With Alirocumab [Phase 2]
Summary
Phase 2 trial update evaluating alirocumab for inhibition of cardiac allograft vasculopathy has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Stanford University | Conditions: Vasculopathy | Phase 2 | Status: COMPLETED